ABRS’ Post

Explore Turkey's pioneering journey in clinical trials with our latest interview, "Charting New Paths: Turkey's Journey in Clinical Trials Discovery." Uncover the advancements and strategies that are propelling clinical research forward in Turkey. This enlightening discussion provides valuable insights into the innovations shaping the future of clinical research. https://lnkd.in/ebaeVFVH

Diversity, equity, inclusion, and accessibility (DEIA) are foundational principles for clinical trials and medical research. In rare diseases clinical research, where numbers of participants are already challenged by rarity itself, maximizing inclusion is of particular importance to clinical trial success, as well as ensuring the generalizability and relevance of the trial results to the people affected by these diseases. In this article, the medical and gray literature and cite case examples to provide insights into how DEIA can be proactively integrated into rare diseases clinical research are reviewed. An interesting paper .

🚀 Register Now: Clinical Trials 2024! 🚀 https://lnkd.in/dJfBPYqV 🌍 Unveiling the Potential of Combined Regional Studies in Emerging Locations 🗓 Tuesday, October 8, 2024 🕚 11:00 AM CEST | 🕒 60-minute webinar The clinical trials landscape is shifting towards emerging regions with faster start-up and enrolment times. For critical areas like oncology and infectious diseases, this speed can make all the difference. Join our expert panel to explore how combined regional studies in Georgia, Armenia, Uzbekistan, and Ukraine can transform patient outcomes, enhance study timelines, and strengthen data integrity. 🔑 Key Takeaways: Streamlined clinical study management Accelerated patient enrolment Strategic partnerships in high-potential markets Ensuring high-quality data and balanced CRA workloads Don’t miss out—register today and gain valuable insights into the future of clinical trials! #ClinicalTrials2024 #EmergingMarkets #Oncology #InfectiousDiseases #PatientCare #Webinar

Join our webinar tomorrow!

Notes from AMP 2024 in Vancouver. Despite the incoming administration's perceived opposition to government regulations, there is a consensus that laboratories should begin preparing for the staged implementation of the FDA final rule, beginning with Phase 1 in May 2025. At the same time, opponents of the rule will pursue litigation, but the time frame for resolution of such litigation and the likelihood of success are highly uncertain. Despite this, many major manufacturers appear to be aggressively selling to existing and new customers in the LDT space. These efforts cross disciplines and include oncology, infectious disease, and pharmacogenomics. Offerings include both existing products and novel ones. Companies that appear to be taking this approach include Thermo-Fisher, Seegene, Revvity, Bio-techne, Agena, Bio-Rad and Eli-tech (feel free to text me if you feel inappropriately included or excluded from this list). These same companies are sharing only limited information about their plans, if any, to develop IVD products in these same areas. Is it fair to conclude that the extensive sales efforts into the LDT space would indicate that the community in general views the likelihood of disruptive LDT restrictions is quite low?

How do you engage with your community? If clinical research doesn’t come to mind, it should. From the scientific community to everyday people living with common and rare conditions, research makes a real difference. Clinical trial awareness starts with education. Learn more at Clinical Trials For All: https://lnkd.in/gTbHuDvt  

How do you engage with your community? If clinical research doesn’t come to mind, it should. From the scientific community to everyday people living with common and rare conditions, research makes a real difference. Clinical trial awareness starts with education. Learn more at Clinical Trials For All: https://lnkd.in/gTbHuDvt

Years ago when I started working in patient care I learned how crucial is to publish in peer reviewed, top tier journals. Natera just passed the milestone of 200 peer reviewed publications. Innovation supported by clinical evidence is part of our DNA. #innovation #genomics

Timely and accurate diagnostics proved to be critical during the COVID-19 pandemic, highlighting a crucial global need: more cost-effective, accessible, and reliable point-of-care and at-home diagnostic technologies. These innovations empower both healthcare providers and patients to take control of the spread of infectious diseases and improve health outcomes. Why is this so important? According to the WHO, diagnostics are among the most essential tools in healthcare, enabling the identification of diseases or health conditions. They are vital not only for prevention, screening, and diagnosis but also for effective case management, treatment, monitoring, and surveillance of both communicable and noncommunicable diseases. Every medical decision begins with a proper diagnosis. Without adequate diagnostic tools, the consequences are far-reaching and severe: delayed or missed diagnoses, misdiagnoses, inappropriate or ineffective treatments (such as the overuse of antibiotics), increased frequency of complications, prolonged hospital stays, rising healthcare costs, erosion of trust in the healthcare system, and even the exacerbation of global health threats like antimicrobial resistance. These challenges disproportionately impact vulnerable populations, deepening the divide caused by poverty and inequality. This is why the work of innovators like Ediphor is so critical. Congratulations to Ediphor Limited team on completing your clinical trial of the second generation device! 🎉 Your efforts are a vital step toward making access to essential diagnostics more equitable, empowering communities, and transforming global health. #diagnostics #HealthcareInnovation #PointofCareTesting #DigitalHealth #HealthTech #PrecisionMedicine #InfectiousDiseases #AMR #PHC #UHC #HealthEquity #PublicHealth #InnovationforImpact

The first video in my Medscape Skills Lab series is out! Check it out! In this first video, I provide an introduction to different phases of clinical trials. https://lnkd.in/gajQFXb6